Procter & Gamble Health Limited
NSE: PGHL BSE: PGHL
NSE
5,395.50
-9.00 (-0.17%)
Prev Close
5404.5
Open Price
5400.5
Volume
32,077
Today Low / High
5342 / 5430
52 WK Low / High
4903.85 / 6739
Range
5,126 - 5,665
BSE
5,394.75
-17.95 (-0.33%)
Prev Close
5412.7
Open Price
5411.05
Volume
602
Today Low / High
5338.9 / 5430
52 WK Low / High
4916 / 6700
Range
5,125 - 5,664
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 5395.5 (target range: 5,126 - 5,665), reflecting a change of -9 (-0.16653%). On the BSE, it is listed at 5394.75 (target range: 5,125 - 5,664), showing a change of -17.95 (-0.33163%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
23 Jan
5,400.50
-0.09%
22 Jan
5,411.00
-0.12%
21 Jan
5,430.50
-0.36%
20 Jan
5,443.00
0.14%
19 Jan
5,445.00
-0.04%
16 Jan
5,374.50
1.24%
14 Jan
5,392.00
-0.20%
13 Jan
5,499.00
-2.05%
12 Jan
5,580.00
-2.22%
09 Jan
5,691.50
-1.98%
08 Jan
5,677.50
0.40%
07 Jan
5,740.50
-0.60%
06 Jan
5,840.00
-1.70%
05 Jan
5,701.50
2.50%
02 Jan
5,711.00
-0.17%
01 Jan
5,679.00
0.77%
31 Dec
5,656.50
0.82%
30 Dec
5,680.00
-0.50%
29 Dec
5,646.00
0.61%
Procter & Gamble Health Limited Graph
Procter & Gamble Health Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Procter & Gamble Health Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 5,395.50, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 5,394.75 | 5,448.70 | 4,903.83 - 5,993.57 |
| 5,502.65 | 4,402.12 - 6,603.17 | ||
| 5,556.59 | 3,889.61 - 7,223.57 | ||
| Bearish Scenario | 5,394.75 | 5,340.80 | 4,806.72 - 5,874.88 |
| 5,286.86 | 4,229.48 - 6,344.23 | ||
| 5,232.91 | 3,663.04 - 6,802.78 |
Overview of Procter & Gamble Health Limited
ISIN
INE199A01012
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
7,360
Market Cap
89,561,965,581
Last Dividend
125
Official Website
IPO Date
2002-07-01
DCF Diff
-10,769.71
DCF
16,165
Financial Ratios Every Investor Needs
Stock Dividend of PGHL
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-08-22 | August 22, 25 | 45 | 45 | 2025-08-22 | 2025-09-25 | |
| 2025-02-21 | February 21, 25 | 80 | 80 | 2025-02-21 | 2025-03-07 | |
| 2024-11-28 | November 28, 24 | 60 | 60 | 2024-11-28 | 2024-12-25 | |
| 2024-02-14 | February 14, 24 | 200 | 200 | 2024-02-14 | 2024-03-03 | |
| 2023-11-23 | November 23, 23 | 50 | 50 | 2023-11-23 | 2023-12-30 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,218.05 Cr | 348.97 Cr | 869.08 Cr | 0.7135 | 2.61 Cr | 190.97 Cr | 633.17 Cr | 251.19 Cr | 151.33 | 362.09 Cr | 0.2062 |
| 2024-03-31 | 1,151.26 Cr | 342.54 Cr | 808.72 Cr | 0.7025 | 3.86 Cr | 215.53 Cr | 536.68 Cr | 200.98 Cr | 121.08 | 303.41 Cr | 0.1746 |
| 2023-03-31 | 1,229.62 Cr | 383.37 Cr | 846.25 Cr | 0.6882 | 5.71 Cr | 206.64 Cr | 559.41 Cr | 229.47 Cr | 138.24 | 318.75 Cr | 0.1866 |
| 2022-03-31 | 1,114.41 Cr | 353.05 Cr | 761.36 Cr | 0.6832 | 6.55 Cr | 168.19 Cr | 477.17 Cr | 192.52 Cr | 115.98 | 264.77 Cr | 0.1728 |
| 2021-03-31 | 1,008.73 Cr | 324.51 Cr | 684.22 Cr | 0.6783 | 3.93 Cr | 155.19 Cr | 437.69 Cr | 176.80 Cr | 106.51 | 242.40 Cr | 0.1753 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 188.55 Cr | 794.20 Cr | 257.24 Cr | 536.9600 Cr | 7.62 Cr | -180.93 Cr | 109.37 Cr | 121.99 Cr | 0.00 Cr | 0.00 Cr | 19.33 Cr | 215.3100 Cr |
| 2024-06-30 | 244.36 Cr | 794.36 Cr | 256.12 Cr | 538.2400 Cr | 9.56 Cr | -234.80 Cr | 109.11 Cr | 131.53 Cr | 0.00 Cr | 0.00 Cr | 11.64 Cr | 218.9100 Cr |
| 2023-06-30 | 435.05 Cr | 1,101.19 Cr | 350.30 Cr | 750.8900 Cr | 12.00 Cr | -423.05 Cr | 134.94 Cr | 173.27 Cr | 54.82 Cr | 0.00 Cr | -12.64 Cr | 303.9000 Cr |
| 2022-06-30 | 319.40 Cr | 893.72 Cr | 277.23 Cr | 616.4900 Cr | 2.83 Cr | -316.57 Cr | 115.21 Cr | 149.62 Cr | 0.56 Cr | 0.00 Cr | -3.83 Cr | 235.8300 Cr |
| 2021-06-30 | 464.05 Cr | 986.16 Cr | 282.45 Cr | 703.7100 Cr | 7.61 Cr | -456.44 Cr | 118.37 Cr | 140.13 Cr | 97.22 Cr | 0.00 Cr | -2.66 Cr | 238.9700 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 175.8400 Cr | 2.4400 Cr | -234.7400 Cr | 167.2800 Cr | -251.6700 Cr | 188.5500 Cr | -8.5600 Cr | 312.5459 Cr | 0.0000 Cr | -232.4000 Cr | -2.3700 Cr |
| 2024-06-30 | 228.2800 Cr | -6.8700 Cr | -418.1100 Cr | 206.5600 Cr | -196.6900 Cr | 238.7300 Cr | -21.7300 Cr | 200.9800 Cr | 0.0000 Cr | -414.9900 Cr | 23.1300 Cr |
| 2023-06-30 | 236.0000 Cr | -21.5000 Cr | -98.4700 Cr | 193.5200 Cr | 116.0200 Cr | 435.4200 Cr | -42.4800 Cr | 314.2000 Cr | 0.0000 Cr | -93.7900 Cr | -32.3900 Cr |
| 2022-06-30 | 169.5200 Cr | -25.5400 Cr | -288.6300 Cr | 131.6000 Cr | -144.6500 Cr | 319.4000 Cr | -37.9200 Cr | 253.3700 Cr | 0.0000 Cr | -283.8500 Cr | -2.0200 Cr |
| 2021-06-30 | 247.2600 Cr | -32.2700 Cr | -386.6300 Cr | 194.6800 Cr | -171.6400 Cr | 464.0500 Cr | -52.5800 Cr | 233.2800 Cr | 0.0000 Cr | -381.7800 Cr | 15.2600 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 324.92 Cr | 128.36 Cr | 196.56 Cr | 0.6049 | 114.19 Cr | 88.54 Cr | 53.34 | 125.22 Cr | 0.2725 |
| 2025-06-30 | 338.74 Cr | 93.99 Cr | 244.75 Cr | 0.7225 | 188.74 Cr | 66.18 Cr | 39.87 | 90.34 Cr | 0.1954 |
| 2025-03-31 | 310.99 Cr | 98.72 Cr | 212.27 Cr | 0.6826 | 163.48 Cr | 61.18 Cr | 36.86 | 80.92 Cr | 0.1967 |
| 2024-12-31 | 309.77 Cr | 75.73 Cr | 234.04 Cr | 0.7555 | 186.99 Cr | 90.90 Cr | 54.76 | 123.54 Cr | 0.2934 |
| 2024-09-30 | 338.74 Cr | 93.99 Cr | 244.75 Cr | 0.7225 | 188.74 Cr | 66.18 Cr | 39.87 | 90.34 Cr | 0.1954 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 286.17 Cr | 0.00 Cr | 286.17 Cr | 139.18 Cr | 127.33 Cr | 639.26 Cr | 114.24 Cr | 894.40 Cr | 274.67 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 188.55 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -536.96 Cr |
| 2025-03-31 | 182.08 Cr | 23.98 Cr | 206.06 Cr | 146.99 Cr | 109.37 Cr | 526.39 Cr | 121.99 Cr | 794.20 Cr | 257.24 Cr |
| 2024-12-31 | 266.43 Cr | 25.83 Cr | 292.26 Cr | 132.24 Cr | 118.78 Cr | 612.49 Cr | 125.27 Cr | 870.15 Cr | 259.69 Cr |
| 2024-09-30 | 0.00 Cr | 0.00 Cr | 244.36 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -538.24 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 66.18 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 78.53 Cr | 49.22 Cr | -0.05 Cr | -133.58 Cr | -84.41 Cr | 182.27 Cr | 266.68 Cr | -3.23 Cr | 45.99 Cr |
| 2024-12-31 | 90.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 82.33 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 16.78 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,631.90 | ₹3,915,474,737,543.00 | ₹1,678,650.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,011.50 | ₹1,595,864,368,670.00 | ₹460,453.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,932.20 | ₹1,330,835,159,168.00 | ₹315,832.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,235.60 | ₹1,028,721,212,318.00 | ₹3,888,844.00 |
| Lupin Limited | LUPIN | ₹2,137.20 | ₹976,270,408,183.00 | ₹578,346.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹882.00 | ₹887,498,379,180.00 | ₹460,318.00 |
| Mankind Pharma Limited | MANKIND | ₹2,107.60 | ₹870,027,969,747.00 | ₹406,697.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,750.50 | ₹687,558,532,500.00 | ₹77,302.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,132.50 | ₹657,757,838,048.00 | ₹511,822.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,967.70 | ₹555,286,531,869.00 | ₹424,174.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,016.40 | ₹548,710,229,945.00 | ₹4,200,664.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,462.80 | ₹371,118,530,090.00 | ₹47,635.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,699.60 | ₹337,276,210,550.00 | ₹73,196.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,530.80 | ₹290,197,644,232.00 | ₹138,093.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,846.00 | ₹289,177,746,000.00 | ₹132,465.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,351.60 | ₹219,624,415,620.00 | ₹259,357.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,319.00 | ₹207,975,000,000.00 | ₹5,165.00 |
| Eris Lifesciences Limited | ERIS | ₹1,385.60 | ₹188,742,124,170.00 | ₹94,274.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,251.00 | ₹170,008,859,139.00 | ₹26,149.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹956.10 | ₹151,417,316,063.00 | ₹139,597.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹764.55 | ₹150,282,336,454.00 | ₹22,821.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹831.95 | ₹149,010,456,347.00 | ₹318,008.00 |
| Cohance Lifesciences Limited | COHANCE | ₹381.60 | ₹145,987,620,624.00 | ₹380,203.00 |
| Granules India Limited | GRANULES | ₹565.00 | ₹137,107,824,540.00 | ₹972,146.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,723.00 | ₹130,968,152,208.00 | ₹65,701.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹883.50 | ₹108,388,663,500.00 | ₹208,914.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,395.50 | ₹89,561,965,581.00 | ₹32,077.00 |
| Strides Pharma Science Limited | STAR | ₹796.25 | ₹73,392,523,523.00 | ₹356,395.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹768.70 | ₹69,680,574,898.00 | ₹277,301.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹424.80 | ₹65,037,754,238.00 | ₹81,217.00 |
| FDC Limited | FDC | ₹369.60 | ₹60,174,607,046.00 | ₹49,065.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹267.00 | ₹52,220,344,872.00 | ₹242,372.00 |
| Sequent Scientific Limited | SEQUENT | ₹201.37 | ₹50,307,022,432.00 | ₹364,240.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.94 | ₹40,545,727,205.00 | ₹476,606.00 |
| Innova Captab Limited | INNOVACAP | ₹678.05 | ₹38,801,363,108.00 | ₹1,793,841.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,135.70 | ₹35,322,374,336.00 | ₹4,017.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹688.40 | ₹34,915,031,882.00 | ₹42,892.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹317.80 | ₹34,629,161,217.00 | ₹174,725.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹370.05 | ₹33,774,463,500.00 | ₹102,103.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹309.70 | ₹31,057,492,108.00 | ₹32,969.00 |
| Suven Life Sciences Limited | SUVEN | ₹134.07 | ₹30,497,439,180.00 | ₹248,500.00 |
Key Executives
MD & Executive Director
Milind Vasant Thatte
Gender: male
Year Born: 1969
CFO & Executive Director
Shashank Srowthy
Gender: male
Year Born:
Director of Sales, Distributor Operations & Sales Stewardship Leader
Vishal Naik
Gender: male
Year Born:
Assistant Company Secretary
Prachi Vichare
Gender: female
Year Born:
Human Resource Leader
Sanika Gokhale
Gender: female
Year Born:
Compliance Officer & Company Secretary
Zeal Bhavin Rupani
Gender: female
Year Born:
FAQs about Procter & Gamble Health Limited
Who is the CEO of the company?
The CEO is Milind Vasant Thatte.
What is the current market price of the stock?
The current price is ₹5,395.50.
What is the 52-week price range?
The range is ₹4903.85-6739.
What is the market capitalization of the company?
The market capitalization is ₹8,956.20 crores.
What is the dividend yield?
The dividend yield is 2.32%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 29.19.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Procter & Gamble Health Limited (ISIN: INE199A01012) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹8,956.20 crores and an average daily volume of 7,360 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹125.